Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

770.64 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jun 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy?
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Move Over Hims & Hers Health: This Insurance Business Could Be the Next Monster Healthcare Stock (Hint: It's Not UnitedHealth)
Hims & Hers Health shares rocketed higher over the last year, rewarding investors. 
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
Market Monitor News June 18 (Jabil, Reddit & Verve Therapeutics UP - Solar Stocks First Solar, Sunrun & SolarEdge DOWN)
Wall Street stays cool despite geopolitical tension, weak retail data, and a meltdown in solar stocks. 
Via Chartmill
Why Verve Therapeutics Stock Is Skyrocketing Today
Via The Motley Fool
Is the Market Bullish or Bearish on Eli Lilly?
Via Benzinga
Surgery Partners Stock Slumps 13% After Company Rejects Bain Capital’s Take-Private Proposal
Chairman of the Independent Committee, Brent Turner, said the best path forward for Surgery Partners is to continue operating as an independent publicly traded company. 
Via Stocktwits
Members of Congress Are Pouring Millions Into These 7 Surprising Stocks
Via The Motley Fool
Verve Therapeutics Stock Rockets 75% Pre-Market After Eli Lilly Agrees To Acquire The Company For Up To $1.3B: Retail Says Offer Is ‘Low’
Lilly will acquire all outstanding shares of Verve for $10.50 per share in cash payable at closing, in addition to a contingent value right (CVR) per share that entitles holders to $3 per share,... 
Via Stocktwits
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments. 
Via Investor's Business Daily
Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition
Eli Lilly is acquiring Verve Therapeutics to strengthen its cardiovascular pipeline with a gene-editing drug targeting PCSK9-linked conditions. 
Via Benzinga
Verve Therapeutics Soars 75% After-Hours Following Report Of $1.3B Eli Lilly Takeover Talks
The deal would double Verve’s market value and expand Lilly’s pipeline of early-stage therapies. 
Via Stocktwits
Why Novo Nordisk Stock Sank by Nearly 4% Today
Via The Motley Fool
These 2 Growth Stocks Are No-Brainer Buys Right Now
Via The Motley Fool
Could Meta and Eli Lilly Trigger the Next Stock Split Boom?
Meta Platforms and Eli Lilly are two stocks that could perform stock splits down the road, and it's not just because of their high share prices. 
Via MarketBeat
Eli Lilly Launches Flat Pricing For Zepbound, Capping Monthly Cost At $499
Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access without insurance barriers. 
Via Benzinga
Eli Lilly To Offer Highest Doses Of Weight-Loss Medicine On Its Digital Health Platform, But Retail Wants More Good News
Healthcare providers can begin prescribing the 12.5 mg and 15 mg vials on July 7, and shipments to patients will start in early August. 
Via Stocktwits
Topics Stocks
Exposures US Equities
Are These 2 High-Flying Growth Stocks Still Worth Buying After Recent Pullbacks?
Via The Motley Fool
Topics Government
Exposures Political
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Via The Motley Fool
Eli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock?
Via The Motley Fool
Benzinga Bulls And Bears: Eli Lilly, Okto, McDonalds — And Israel-Iran Conflict Sparks Oil Surge
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
1 Growth Stock Down 9% to Buy Right Now
Via The Motley Fool
Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased
Jefferies thinks big pharma companies are "still on the hunt" for deals. 
Via Stocktwits
Exposures Product Safety
$1000 Invested In Eli Lilly 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock
Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick with strong growth potential. 
Via Benzinga
Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company
Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory discussions. 
Via Benzinga
Down 12%, Should You Buy the Dip on Eli Lilly?
Via The Motley Fool
3 Healthcare Stocks with Questionable Fundamentals
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?
Via The Motley Fool
2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility
Via The Motley Fool
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
1 Profitable Stock with Impressive Fundamentals and 2 to Avoid
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.